629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II

SOUNDTRACK B A phase 2 single arm study to evaluate the efficacy and safety of surovatamig AZD0486 in relapsed or refractory B cell non Hodgkin lymphoma

Real world outcomes with bispecific antibody therapies for aggressive B cell lymphomas in octogenarians

Phase 2 3 trial of zilovertamab vedotin plus standard of care in relapsed refractory diffuse large B cell lymphoma Updated analysis of waveline 003

Glofitamab plus gemcitabine and oxaliplatin GemOx vs rituximab R GemOx in patients with relapsed refractory R R diffuse large B cell lymphoma DLBCL Efficacy and safety in patient subgroups

Efficacy and safety of the polatuzumab acalabrutinib rituximab and lenalidomide Pola AR2 regimen as first line therapy in unfit or frail patients with diffuse large B cell lymphoma

Efficacy and safety of CAR T cell therapy versus bispecific antibodies in patients with relapsed refractory B cell non Hodgkin lymphoma A single arm meta analysis

Phase 1 study of MK 1045 a novel CD19xCD3 T cell engager in participants with relapsed or refractory diffuse large B cell lymphoma

A chemo free tumor microenvironment TME reshaping regimen combining glofitamab induces a high CR rate in relapsed refractory diffuse large B cell lymphoma DLBCL

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non Hodgkin lymphoma patients – the geltamo Spanish Lymphoma Group experience

Epcoritamab GemOx achieves durable 2 year remissions in relapsed refractory R R 2L diffuse large B cell lymphoma DLBCL Long term data reinforce clinical potential of the regimen across a diverse patient population

Fixed duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B cell lymphoma 3 year follow up from a Phase Ib II study

Comprehensive analysis of bridging to CAR T cell therapy in large B cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

Outcomes and treatment patterns of patients with primary mediastinal b cell lymphoma after CAR t cell therapy failure A descar t analysis